zifaxaban

Zifaxaban is an orally active, small molecule direct Factor Xa inhibitor developed by the Tianjin Institute of Pharmaceutical Research (TIPR). It is being investigated for the prevention and treatment of venous thromboembolic diseases, including deep vein thrombosis (DVT) and pulmonary embolism. As a member of the "xaban" class of anticoagulants, zifaxaban works by selectively and reversibly binding to the active site of Factor Xa, which is a critical protease in the coagulation cascade. By inhibiting Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby blocking the final common pathway of blood coagulation and the subsequent formation of fibrin clots. Zifaxaban is part of a strategic effort by Chinese pharmaceutical developers to produce domestic alternatives to established global Factor Xa inhibitors like rivaroxaban and apixaban.

Other names

zifaxabanum